Lyell Immunopharma (LYEL) Change in Cash (2020 - 2026)

Lyell Immunopharma has reported Change in Cash for 7 years, with the latest figure at $30.6 million in Q1 2026.

• Quarterly Change in Cash rose 107.69% year-over-year to $30.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.7 million (down 656.63% YoY) and the FY2025 annual result came in at -$45.5 million, down 17.8% from the prior year.
• Change in Cash advanced to $30.6 million in Q1 2026 per LYEL's latest filing, from -$63.4 million in the prior quarter.
• Over five years, Change in Cash peaked at $114.9 million in Q2 2023 and troughed at -$140.6 million in Q4 2023.
• A 5-year average of -$11.9 million and a median of -$14.1 million in 2023 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 781.89% in 2023, down 2040.45% in 2023.
• Over 5 years, Change in Cash stood at $7.2 million in 2022, then plunged by 2040.45% to -$140.6 million in 2023, then jumped by 104.77% to $6.7 million in 2024, then plunged by 1046.18% to -$63.4 million in 2025, then soared by 148.25% to $30.6 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $30.6 million, -$63.4 million, and $24.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.